Skip to main content

A phase 1 study of IO-202, an antibody targeting LILRB4, in patients with monocytic differentiation AML and CMML


Immune-Onc Therapeutics


TAP Partner

Project Term: March 5, 2021 - TBD

In March 2021, LLS made an equity investment in Immune-Onc Therapeutics to support the "Phase 1 Clinical Development of IO-202, An Antibody Targeting LILRB4, for the Treatment of AML with Monocytic Differentiation and CMML." The company’s work builds on early research by Chengcheng (Alec) Zhang, Ph.D. at the University of Texas Southwestern Medical Center that was also funded by LLS grants. The lead candidate, called IO-202, a first-in-class antibody targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) member 4 (LILRB4), has entered a phase 1 clinical trial for the treatment of advanced acute myeloid leukemia and chronic myelomonocytic leukemia.

Lay Abstract

For additional information, please visit

Therapy Acceleration Program
To All Projects